Table 1:

Guidelines and Health Technology Assessment Recommendations on Use of Pharmacogenomic Testing for Guiding Treatment Among People With Depression

Agency, Year	Recommendation or Statement
APA Task Force for Biomarkers and Novel Treatments, 201823	“[T]here is insufficient evidence to support widespread use of combinatorial pharmacogenetic decision support tools at this point in time”
CANMAT, 20166	“… CANMAT does not recommend routine use of pharmacogenetic testing. … Pharmacogenetic testing and/or TDM may be helpful in individual circumstances, including inability to tolerate minimum doses (i.e., to detect poor metabolizers), repeated failure to respond to high doses (i.e., to detect ultrarapid metabolizers), and to detect nonadherence”
Washington State HealthCare Authority, 201639	“Based on these findings the committee voted to not cover pharmacogenomic testing for selected conditionsa”
EGAPP Working Group, 200727	“[We] found insufficient evidence to support a recommendation for or against use of CYP450 testing in adults beginning SSRI treatment for non-psychotic depression. In the absence of supporting evidence, and with consideration of other contextual issues, EGAPP discourages use of CYP450 testing for patients beginning SSRI treatment until further clinical trials are completed”

Abbreviations: APA, American Psychiatric Association; CANMAT, Canadian Network for Mood and Anxiety Treatments; CYP450, cytochrome P450; EGAPP, Evaluation of Genomic Applications in Practice and Prevention; SSRI, selective serotonin reuptake inhibitor; TDM, therapeutic drug monitoring.

^aSelected conditions include depression, mood disorders, psychosis, anxiety, ADHD (attention deficit hyperactivity disorder), and substance use disorder.